ImmuCell Corporation (ICCC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ICCC Stock Summary
- ICCC has a higher market value than just 10.12% of US stocks; more precisely, its current market capitalization is $71,751,596.
- ICCC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 220.62 -- higher than 87.55% of US-listed equities with positive expected earnings growth.
- ICCC's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 20.83% of US stocks.
- Stocks that are quantitatively similar to ICCC, based on their financial statements, market capitalization, and price volatility, are SINT, MOSY, SCYX, MNDO, and ONTX.
- ICCC's SEC filings can be seen here. And to visit Immucell Corp's official web site, go to immucell.com.
ICCC Valuation Summary
- In comparison to the median Healthcare stock, ICCC's price/earnings ratio is 547.67% lower, now standing at -163.4.
- ICCC's EV/EBIT ratio has moved down 172.5 over the prior 243 months.
- Over the past 243 months, ICCC's price/sales ratio has gone up 3.4.
Below are key valuation metrics over time for ICCC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ICCC | 2021-08-31 | 4.4 | 2.2 | -163.4 | -164.0 |
| ICCC | 2021-08-30 | 4.3 | 2.2 | -161.3 | -161.9 |
| ICCC | 2021-08-27 | 4.2 | 2.1 | -156.9 | -157.4 |
| ICCC | 2021-08-26 | 4.3 | 2.2 | -160.6 | -161.2 |
| ICCC | 2021-08-25 | 4.2 | 2.1 | -154.8 | -155.3 |
| ICCC | 2021-08-24 | 4.1 | 2.0 | -152.3 | -152.8 |
ICCC Growth Metrics
- Its 4 year cash and equivalents growth rate is now at 73.31%.
- Its year over year revenue growth rate is now at 2.22%.
- The 4 year net income to common stockholders growth rate now stands at -231.67%.
The table below shows ICCC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 16.11482 | -0.403793 | -0.434248 |
| 2021-03-31 | 14.53896 | -0.165421 | -1.341154 |
| 2020-12-31 | 15.3422 | 1.315578 | -1.022117 |
| 2020-09-30 | 15.23075 | 1.112708 | -1.521399 |
| 2020-06-30 | 14.47873 | 1.713629 | -1.701046 |
| 2020-03-31 | 14.2227 | 0.413767 | -1.562409 |
ICCC Price Target
For more insight on analysts targets of ICCC, see our ICCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ICCC Stock Price Chart Interactive Chart >
ICCC Price/Volume Stats
| Current price | $9.33 | 52-week high | $13.20 |
| Prev. close | $9.15 | 52-week low | $5.21 |
| Day low | $9.15 | Volume | 3,700 |
| Day high | $9.43 | Avg. volume | 24,589 |
| 50-day MA | $9.24 | Dividend yield | N/A |
| 200-day MA | $9.56 | Market Cap | 72.23M |
ImmuCell Corporation (ICCC) Company Bio
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was founded in 1982 and is headquartered in Portland, Maine.
Latest ICCC News From Around the Web
Below are the latest news stories about Immucell Corp that investors may wish to consider to help them evaluate ICCC as an investment opportunity.
ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021PORTLAND, Maine, Oct. 06, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter ended September 30, 2021. Preliminary, Unaudited Total Sales Results: 2021 2020 $ Increase % IncreaseDuring the Three-Month |
Raffael Lichdi, DVM Joins ImmuCells Sales & Marketing TeamPORTLAND, Maine, Sept. 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (ImmuCell or the Company), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the expansion of its commercial team with the hiring of Dr. Raffael Lichdi as Commercial Research & Technical Services Veterinarian. |
Raffael Lichdi, DVM Joins ImmuCell’s Sales & Marketing TeamPORTLAND, Maine, Sept. 14, 2021 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the expansion of its commercial team with the hiring of Dr. Raffael Lichdi as Commercial Research & Technical Services Veterinarian. Dr. Lichdi blends exceptional technical know-how |
Is ImmuCell (NASDAQ:ICCC) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says... |
Portlands ImmuCell targeted by New York law firm over FDA setbackThe law firm issued a solicitation for plaintiffs after some bad news about a product under development caused the company''s stock price to drop. |
ICCC Price Returns
| 1-mo | -4.41% |
| 3-mo | -8.89% |
| 6-mo | -12.39% |
| 1-year | 61.70% |
| 3-year | 12.41% |
| 5-year | 55.50% |
| YTD | 56.81% |
| 2020 | 15.53% |
| 2019 | -26.95% |
| 2018 | -19.80% |
| 2017 | 47.73% |
| 2016 | N/A |
Continue Researching ICCC
Want to see what other sources are saying about Immucell Corp's financials and stock price? Try the links below:Immucell Corp (ICCC) Stock Price | Nasdaq
Immucell Corp (ICCC) Stock Quote, History and News - Yahoo Finance
Immucell Corp (ICCC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...